Rapamycin: <b>Rapamycin Holdings</b> Opens Investigational New Animal Drug Application With The FDA Center For Veterinary Medicine

SAN ANTONIO--(www.businesswire.com/">BUSINESS WIRE)--Privately-held Rapamycin Holdings, Inc. (RHI), based in San Antonio, has opened an Investigational New Animal Drug (INAD) application for the therapeutic use of the companys eRapa-NP2gTM compound in the treatment of Feline Chronic Gingivostomatitis (FCGS).